RPN2

Across TCGA pan-cancer cohorts, RPN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPN2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPN2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where RPN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.978	0.814	.004	20	view →
CCRCC	DFS	Tertile	III,IV	0.393	0.768	.008	11	view →
LSCC	DFS	Median	II,III,IV	0.644	0.903	.016	9	view →
HNSC	DFS	Tertile	III,IV	0.910	0.710	.018	6	view →
PDAC	DFS	Median	IV	0.203	0.678	.021	3	view →
GBM	DFS	Quartile	All	0.690	0.823	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPN2–LUAD (DFS)

Open the LUAD breakdown →